I disse virustider fant jeg denne godbiten. Imotsetning til selskap som jobber med en vaksine har disse et produkt som Kina har satt inn i kamp mot Covid 19.
MCAP 195MUSD.
In addition, in collaboration with its partner, China Medical System Holdings Limited (CMS) (HKG:0867), a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China, CytoSorbents has conducted the initial training of key critical care physicians at these hospitals in order to treat patients where indicated. The rationale of CytoSorb blood purification treatment in COVID-19 coronavirus infected patients is to control the “cytokine storm” and massive systemic inflammatory response that can lead to organ failure, such as lung failure and circulatory collapse, as described in this Washington Post article entitled, “How the coronavirus can kill people.” To date, the COVID-19 coronavirus has infected over 81,000 people, killing nearly 3,000 globally, according to the World Health Organization. Although the majority of cases have been in China, many new infections are being reported in countries around the world, including the United States, with Italy, South Korea, Japan, Iran, Singapore, Taiwan, and Thailand reporting a recent surge in the numbers of coronavirus cases.
Allerede godkjent i en rekke land og Tyskland ser ut til å være største marked pr nå. Blir spennende å se om Tyskland får en lavere dødsrate enn andre land. Kan være en indikasjon på at dette produktet har livets rett.
The clinical features of the COVID-19 coronavirus, relationship to cytokine storm, and potential role of CytoSorb in treating patients suffering from severe coronavirus infection were described in the press release entitled, “CytoSorb, the Wuhan Coronavirus, and Cytokine Storm.” Furthermore, the use of extracorporeal therapies, such as CytoSorb, were highlighted in a recent publication in Lancet Respiratory Medicine by Drs. Claudio Ronco, Paolo Navalesi, and Jean Louis Vincent entitled, “Coronavirus epidemic: preparing for extracorporeal organ support in intensive care.” Notably the authors state, “A sepsis-like syndrome might occur frequently due to the virus itself or to a superimposed bacterial infection and in this case, since pharmacological approaches have shown poor results, new extracorporeal organ support therapies including haemoadsorption and haemoperfusion, with new sorbent cartridges designed to remove cytokines and other circulating mediators, should be considered.” These publications provide the rationale to potentially use CytoSorb, the first specifically-approved extracorporeal cytokine adsorber in the European Union, in this setting.
Har du handlet?
